Story
Agios Pharmaceuticals Shares Plunge After Halting Sickle Cell Drug Trial

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) plunged 14% in trading on Tuesday after the company announced it was discontinuing the development of tebapivat, an experimental treatment for sickle cell disease. The decision followed a review of Phase 2 clinical trial data that failed to show a significant enough benefit to warrant further investment.
Trial Data Fails to Differentiate
Agios stated that the Phase 2 trial of tebapivat, an oral pyruvate kinase activator, did not demonstrate a sufficient level of differentiation to support its advancement. The 12-week study involved 59 patients with sickle cell disease and measured hemoglobin response as its primary endpoint.
While the company noted improvements in hemoglobin levels, the response rates did not clearly outperform the placebo group across all doses. Key results from the trial included:
- Placebo: 33.3% response rate
- 2.5 mg dose: 43.8% response rate
- 5.0 mg dose: 47.1% response rate
- 7.5 mg dose: 29.4% response rate
AdThe company confirmed that the safety and tolerability profile of tebapivat was consistent with findings from previous trials.
Focus Shifts to Mitapivat
Following the discontinuation of tebapivat, Agios will increase its focus on its other pyruvate kinase activator, mitapivat, for the same indication. This drug represents the company's lead asset in its sickle cell disease pipeline.
Investors will be closely watching for developments with mitapivat, which is currently under Priority Review with the U.S. Food and Drug Administration (FDA). The agency accepted the company's supplemental New Drug Application for accelerated approval earlier this month and has set a Prescription Drug User Fee Act (PDUFA) goal date of November 1, 2026.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.